Trial Profile
A Study to Evaluate the Efficacy of Intravitreal Aflibercept on Pigment Epithelial Detachments (PED) Associated With Previously Treated Patients With Neovascular Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal detachment
- Focus Therapeutic Use
- 18 May 2016 New trial record